Evidence map›Paper›PMID 39641273›Full record

ArticleJCI insight2024

Brain region-specific neural activation by low-dose opioid promotes social behavior.

Soichiro Ohnami, Megumi Naito, Haruki Kawase, Momoko Higuchi, Shigeru Hasebe, Keiko Takasu, Ryo Kanemaru, Yuki Azuma, Rei Yokoyama, Takahiro Kochi and 11 more

Abstract read
In one paragraph

Article in JCI insight, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Epigenetic mechanisms of HIV and opioid-induced neuropathology: Potential therapies and interventions.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Soichiro OhnamiLaboratory for Drug Discovery and Disease Research, Shionogi & Co. Ltd., Toyonaka, Osaka, Japan.
Megumi NaitoLaboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, and.
Haruki KawaseLaboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, and.
Momoko HiguchiLaboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, and.
Shigeru HasebeDepartment of Pharmacology, Graduate School of Dentistry, Osaka University, Suita, Osaka, Japan.
Keiko TakasuLaboratory for Drug Discovery and Disease Research, Shionogi & Co. Ltd., Toyonaka, Osaka, Japan.
Ryo KanemaruShionogi TechnoAdvance Research Co. Ltd., Toyonaka, Osaka, Japan.
Yuki AzumaLaboratory for Drug Discovery and Disease Research, Shionogi & Co. Ltd., Toyonaka, Osaka, Japan.
Rei YokoyamaLaboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, and.
Takahiro KochiDepartment of Dental Anesthesiology, and.
Eiji ImadoDepartment of Cellular and Molecular Pharmacology.
Takeru TaharaDepartment of Neurochemistry and Environmental Health Sciences, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Hiroshima, Japan.
Yaichiro KotakeDepartment of Neurochemistry and Environmental Health Sciences, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Hiroshima, Japan.
Satoshi AsanoDepartment of Cellular and Molecular Pharmacology.
Naoya OishiSK Project, Medical Innovation Center, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan.
Kazuhiro TakumaDepartment of Pharmacology, Graduate School of Dentistry, Osaka University, Suita, Osaka, Japan.
Hitoshi HashimotoLaboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, and.
Koichi OgawaLaboratory for Drug Discovery and Disease Research, Shionogi & Co. Ltd., Toyonaka, Osaka, Japan.
Atsushi NakamuraLaboratory for Drug Discovery and Disease Research, Shionogi & Co. Ltd., Toyonaka, Osaka, Japan.
Hidekuni YamakawaLaboratory for Drug Discovery and Disease Research, Shionogi & Co. Ltd., Toyonaka, Osaka, Japan.
Yukio AgoLaboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, and.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The opioid system plays crucial roles in modulating social behaviors in both humans and animals. However, the pharmacological profiles of opioids regarding social behavior and their therapeutic potential remain unclear. Multiple pharmacological, behavioral, and immunohistological c-Fos mapping approaches were used to characterize the effects of μ-opioid receptor agonists on social behavior and investigate the mechanisms in naive mice and autism spectrum disorder-like (ASD-like) mouse models, such as prenatally valproic acid-treated mice and Fmr1-KO mice. Here, we report that low-dose morphine, a μ-opioid receptor agonist, promoted social behavior by selectively activating neurons in prosocial brain regions, including the nucleus accumbens, but not those in the dorsomedial periaqueductal gray (dmPAG), which are only activated by analgesic high-dose morphine. Critically, intra-dmPAG morphine injection counteracted the prosocial effect of low-dose morphine, suggesting that dmPAG neural activation suppresses social behavior. Moreover, buprenorphine, a μ-opioid receptor partial agonist with less abuse liability and a well-established safety profile, ameliorated social behavior deficits in two mouse models recapitulating ASD symptoms by selectively activating prosocial brain regions without dmPAG neural activation. Our findings highlight the therapeutic potential of brain region-specific neural activation induced by low-dose opioids for social behavior deficits in ASD.

Indexed as

Analgesics, OpioidMice, KnockoutMorphinePeriaqueductal GrayReceptors, Opioid, muSocial BehaviorAnimalsAutism Spectrum DisorderBehavior, AnimalBrainBuprenorphineDisease Models, AnimalFemaleFragile X Messenger Ribonucleoprotein 1MaleMiceAnalgesics, OpioidBuprenorphineFmr1 protein, mouseFragile X Messenger Ribonucleoprotein 1MorphineReceptors, Opioid, muValproic AcidBehaviorNeurodevelopmentNeurosciencePharmacologyTherapeutics

Identifiers

PMID39641273
PMCPMC11623950

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.